CV
CVSI.US CV Sciences Inc
- Market cap
- USD 2.26M
- P/E
- -
- P/B
- 1.28x
- ROE
- -180.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is CVSI.US undervalued?
Graham numberThe Graham number of CV Sciences Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
CV Sciences Inc fundamental analysis
No fundamental analysis for CV Sciences Inc yet.
CV Sciences Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About CV Sciences Inc
CV Sciences, Inc. engages in the development, manufacture, marketing, and sale of herbal supplements, hemp-based cannabidiol (CBD), and plant-based food products in North America. It offers its products under the PlusCBD, PlusCBD Pet, PlusHLTH, Cultured Foods, and Lunar Fox brand names in the health care market sector, including nutraceutical, beauty care, specialty foods, and pet products through its websites, select distributors, brick and mortar retailers, and select e-ta…
Full company profileCV Sciences Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
CV Sciences Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 11.1M | 20.7M | 48.2M | 53.7M | 24.4M | 20.0M | 16.2M | 16.0M | 15.7M | 13.8M | 12.4M |
| Gross Profit | 7.00M | 14.5M | 33.9M | 35.1M | 11.0M | 8.62M | 5.55M | 7.09M | 7.17M | 6.75M | 6.02M |
| Operating Income | -6.91M | -2.49M | 10.2M | -17.2M | -22.6M | -18.4M | -6.85M | 3.36M | -2.19M | -470K | -1.24M |
| EBITDA | - | -4.69M | 10.8M | -16.5M | -21.7M | -14.3M | -5.73M | 3.60M | -1.86M | -240K | -2.08M |
| Net Income | -14.1M | -4.90M | 10.0M | -16.6M | -22.3M | -15.6M | -8.21M | 3.10M | -2.39M | -958K | -2.84M |
| EPS | - | -0.05 | 0.11 | -0.17 | -0.22 | -0.14 | -0.05 | 0.02 | -0.01 | -0.01 | -0.01 |
| Balance Sheet | |||||||||||
| Total Assets | 18.6M | 22.7M | 36.9M | 52.7M | 30.6M | 18.1M | 12.7M | 9.20M | 7.93M | 6.96M | 6.52M |
| Total Liabilities | 5.38M | 6.33M | 6.79M | 23.5M | 19.4M | 14.5M | 13.5M | 6.30M | 6.13M | 5.49M | 4.95M |
| Shareholders' Equity | 13.2M | 16.4M | 30.1M | 29.1M | 11.2M | 3.54M | -777K | 2.90M | 1.80M | 1.47M | 1.57M |
| Cash & Short-term Investments | 782K | 2.01M | 12.7M | 9.11M | 4.02M | 1.38M | 611K | 1.32M | 454K | 278K | 266K |
| Cash Flow | |||||||||||
| Operating Cash Flow | -2.05M | 3.62M | 12.6M | -2.23M | -7.30M | -7.49M | -1.89M | 2.25M | -861K | -407K | 242K |
| Capital Expenditure | 17.2K | 454K | 893K | 1.15M | 1.06M | 35.0K | 0.00 | 0.00 | 18.0K | 109K | 20.0K |
| Free Cash Flow | - | 1.61M | 11.3M | -3.37M | -8.36M | -7.52M | -1.89M | 2.25M | -879K | -516K | 222K |
| Ratios | |||||||||||
| ROE | -107.1% | -29.9% | 33.2% | -57.0% | -198.8% | -439.0% | - | 106.9% | -133.4% | -65.3% | -180.5% |
| ROA | -76.1% | -21.6% | 27.1% | -31.5% | -72.8% | -86.1% | -64.5% | 33.7% | -30.2% | -13.8% | -43.5% |
| Net Profit Margin | -127.9% | -23.7% | 20.7% | -30.9% | -91.2% | -77.6% | -50.7% | 19.4% | -15.2% | -6.9% | -22.9% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
CV Sciences Inc dividends
CV Sciences Inc has not paid dividends in the last 9 fiscal years.
Who owns CV Sciences Inc
- Insiders 20.48%
- Institutions 0.00%
- Public & others 79.52%
- Shares outstanding 226M
- Free float 183M
CV Sciences Inc company profile
- Company name
- CV Sciences Inc
- Ticker
- CVSI.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Personal Care Products
- Employees
- 42
- Fiscal year end
- December
- Address
- 9530 Padgett Street, San Diego, CA, United States, 92126
- Phone
- 866 290 2157
- Website
- cvsciences.com
About CV Sciences Inc
CV Sciences, Inc. engages in the development, manufacture, marketing, and sale of herbal supplements, hemp-based cannabidiol (CBD), and plant-based food products in North America. It offers its products under the PlusCBD, PlusCBD Pet, PlusHLTH, Cultured Foods, and Lunar Fox brand names in the health care market sector, including nutraceutical, beauty care, specialty foods, and pet products through its websites, select distributors, brick and mortar retailers, and select e-tailers. The company was formerly known as CannaVest Corp. and changed its name to CV Sciences, Inc. in January 2016. CV Sciences, Inc. was incorporated in 2010 and is based in San Diego, California.
CV Sciences Inc management
5- Mr. Joseph D. DowlingCEO, Secretary & Director · born 1957
- Mr. Joerg GrasserChief Financial Officer · born 1975
- Mr. Brendan HawkinsInvestor Relations
- Mr. Jesse KaragianesSenior Vice President of Revenue Growth
- Ms. Alyssa DunnOperations Manager